U.S. and Plaintiff States v. Apple, Inc., No. 2:24-cv-04055 (D.N.J. Mar. 21, 2024)
Sixteen states and the U.S. Department of Justice filed a civil antitrust lawsuit against Apple for monopolization or attempted monopolization of smartphone markets in violation of Section 2 of the Sherman Act. The complaint, filed in the United States District Court for the District of New Jersey, alleges that Apple illegally maintains a monopoly over…
Ohio et al. v. National Collegiate Athletic Association (NCAA), No. 1:23-cv-00100 (N.D. W.V. Dec. 7, 2023)
Seven plaintiff states filed suit against the NCAA, alleging that the NCAA’s transfer eligibility rule is an illegal restraint on college athletes’ ability to market their labor and control their education. The rule requires college athletes who transfer among Division 1 schools to wait one year before competing in games, unless they obtain a waiver…
FTC and Plaintiff States v. Amazon.com, Inc., No. 2:23-cv-01495 (W.D. Wash. Sept. 26, 2023)
The FTC and plaintiff states alleged that Amazon, an online retail and technology company, is a monopolist that uses a set of interlocking anticompetitive and unfair strategies to illegally maintain its monopoly power. The lawsuit alleges that Amazon’s actions allow it to stop rivals and sellers from lowering prices, degrade quality for shoppers, overcharge sellers,…
FTC and Plaintiff States v. Amgen, No. 23-CV-3053 (N.D. Ill. 06/22/23)
Plaintiff states joined the Federal Trade Commission’s suit against Amgen’s planned $28 billion purchase of Horizon Therapeutics. The plaintiffs sought a temporary restraining order and preliminary injunction blocking Amgen Inc. and its subsidiaries from completing the proposed acquisition. Horizon Therapeutics PLC makes the only U.S. FDA-approved treatment for thyroid eye disease, Tepezza, and the only FDA-approved…
Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)
44 plaintiff states filed suit against Teva Pharmaceuticals and 19 of the nation’s largest generic drug manufacturers alleging a broad conspiracy to artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade for more than 100 different generic drugs. The lawsuit was originally Connecticut, was transferred to the MDL court in Pennsylvania. The lawsuit…
New York et al. v. Meta (originally Facebook Inc.), No. 20-3589 (D.D.C.)
Forty-eight plaintiff states filed a lawsuit against Facebook Inc., alleging that the company harms the public by illegally stifling competition to protect its monopoly power. The states alleged that, over the last decade, the social networking giant illegally acquired competitors in a predatory manner and cut services to smaller firms that threatened its power, depriving…
U.S. et al. v. JetBlue Airways Corp., No. 1:23-cv-10511 (D. Mass. Mar. 31, 2023)
The U.S. Department of Justice and seven states sued to block JetBlue’s takeover of Spirit Airlines, alleging that the deal would lessen competition and potentially increase costs and decrease reliability for passengers. According to the complaint, Spirit is a budget airline whose presence in a city pair may cause other airlines to lower their prices. …
United States et al. v. Google LLC, No. 1:23-cv-00108 (E.D. Va. Jan. 24, 2023)
The United States and eight plaintiff states sued Google for monopolizing multiple digital advertising technology products in violation of Sections 1 and 2 of the Sherman Act. The complaint alleges that Google monopolizes key digital advertising technologies, collectively referred to as the “ad tech stack,” that website publishers depend on to sell ads and that…
Settlement Agreement Between Plaintiff States and Citibank (June 2018)
Forty-two plaintiff states reached a $100 million settlement with Citibank for fraudulent conduct involving interest rate manipulation that had a significant impact on consumers and financial markets around the world. UBS’ fraudulent conduct involved the manipulation of LIBOR (the London Interbank Offered Rate). LIBOR is a benchmark interest rate that affects financial instruments worth trillions…
